Replies to The trial was RucaPANC for maintenance monotherapy and targeted BRCA1, BRCA2, PALB2 mutations using the PARP-1…

Discussion

Pancreatic Cancer | Last Active: Sep 5, 2023 | Replies (58)

Comment receiving replies

@stageivsurvivor

The trial was RucaPANC for maintenance monotherapy and targeted BRCA1, BRCA2, PALB2 mutations using the PARP-1 inhibitor Rucaparib (Rubraca).

More details on the trial-

PARP STUDY AT PennMedicine
https://ascopubs.org/doi/10.1200/PO.17.00316
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057747/
This is a YouTube video of my case by pancreatic cancer oncologist Dr. Kim Reiss-Binder at PennMedicine. It starts at time stamp 1:00 and the conclusion is at the end of the presentation.

Replies to "The trial was RucaPANC for maintenance monotherapy and targeted BRCA1, BRCA2, PALB2 mutations using the PARP-1..."

pendesk8 | @pendesk8 | Dec 24, 2022

thank you .

gardenlady1116 | @gardenlady1116 | Mar 4, 2023

Outstanding!!!!!! I will send to family members with BRCA1.

pendesk8 | @pendesk8 | May 25, 2023

I am going to NCI in bethesda ,Md in june for screening for a clinical trial for my ATM gene mutation.